Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GoFintech Quantum Innovation Limited
國富量子創新有限公司

(formerly known as GoFintech Innovation Limited 國富創新有限公司)
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 290)

Website: https://290.com.hk

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION WITH
QUREGENAI (SUZHOU) BIOTECHNOLOGY CO., LTD.*

This announcement is made by GoFintech Quantum Innovation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that on 8 May 2026, the Company entered into a non-legally binding strategic cooperation memorandum of understanding (the "**MOU**") with 醫圖生科(蘇州)生命科學技術有限公司 (QureGenAI (Suzhou) BioTechnology Co., Ltd.*) ("**QureGenAI Biotech**") in relation to the strategic cooperation (the "**Strategic Cooperation**") between the Company and QureGenAI Biotech (collectively, the "**Parties**").

MEMORANDUM OF UNDERSTANDING

The principal terms of the MOU are as follows:

Date:	8 May 2026
Parties:	(1) the Company; and
	(2) QureGenAI Biotech

Pursuant to the MOU, the Parties intend to collaborate in the following areas through a milestone-based licensing model:

(i) Asset Licensing and Acquisition: The Parties agreed to use joint venture companies to jointly operate QureGenAI Biotech's quantum computing drug discovery systems (including the QureGenAI and TyxonQ platforms (the "**Quantum AIDD Platforms**")) through licensing arrangement and would further acquire the Quantum AIDD Platforms and drug pipelines through milestone-based steps;

(ii) Industrial Fund: The Parties agreed to jointly initiate the establishment of a quantum frontier technology investment fund which will invest in the development of specialized quantum chips for the biopharmaceutical and materials sectors, as well as other frontier areas of quantum technology; and

(iii) Quantum Computing Center: The Parties will, in accordance with relevant policies, jointly establish a quantum computing center in Hong Kong with a focus on the research and development of quantum computing application technologies and related innovation work.

The Parties agree to complete the negotiation and finalize the formal definitive agreement of the Strategic Cooperation within 90 days from the date of signing of the MOU.

Further announcement(s) will be published by the Company in relation to the Strategic Cooperation as and when appropriate.

INFORMATION ABOUT QUREGENAI BIOTECH

QureGenAI Biotech is a leading high-tech enterprise established in the People's Republic of China. It is dedicated to revolutionizing drug discovery through artificial intelligence ("**AI**") and quantum computing, combining cutting-edge computational methods with life sciences to accelerate pharmaceutical innovation.

It possesses legal ownership and intellectual property rights over the Quantum AIDD Platforms, namely QureGenAI and TyxonQ, which provide full-stack integrated computing infrastructure and services for drug development and new material design. The Quantum AIDD Platforms combine quantum simulation, optimization, and machine learning with production-grade quantum chemistry tools, enabling end-to-end solutions for drug discovery and materials science. The Quantum AIDD Platforms form a synergistic ecosystem where cutting-edge quantum computing directly empowers next-generation drug development.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, as at the date of this announcement, QureGenAI Biotech and its ultimate beneficial owners are third parties independent of and not connected with the Company and its connected person (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

REASONS FOR AND BENEFITS OF THE MOU

The Group is principally engaged in the operation of a financial technology investment platform that combines licensed financial services with strategic technology investments. The Group is a cross-border, cross-industry investment platform based in Hong Kong, backed by the Greater Bay Area, and focused on the international market, with a strong presence in the financial services sector. The Group currently also implements an innovation-driven strategy, actively investing in the quantum technology industry and exploring multi-dimensional layout in the field of quantum technology at the business level.

As a diversified financial services platform, the Group has been seeking to explore different cooperation opportunities within the quantum technology and AI fields. In April 2026, the Group and QureGenAI Biotech established a joint venture company in the British Virgin Islands which marks the commencement of the Group's strategic expansion into the quantum AI drug discovery sector. The Board believes that the Strategic Cooperation represents an opportunity for the Group: (a) to further explore the developments in cutting-edge technology sectors and the potential integration of its resources with the QureGenAI Biotech's infrastructures, such as the QureGenAI and TyxonQ platforms; and (b) to target sectors such as drug discovery and new material design, leveraging QureGenAI Biotech's existing drug pipelines and quantum-AI computing assets to explore the diversification of the Group's potential revenue streams.

In addition, the Board believes that the potential integration of the respective management and technical resources with QureGenAI Biotech will enhance the Group's technical competitiveness in the "Quantum-AI" convergence era and the Strategic Cooperation will allow the Group to leverage its management resources alongside QureGenAI Biotech's technical expertise.

As such, the Board considers that the entering into of the MOU is in the interests of the Company and its shareholders as a whole and will create sustainable value for the shareholders of the Company.

GENERAL

The Board wishes to emphasise that no formal or legally binding agreement in relation to the Strategic Cooperation has been entered into between the Company and QureGenAI Biotech (and/or its respective affiliates) as at the date of this announcement. As such, the Strategic Cooperation may or may not be materialised.

Shareholders and potential investors of the Company should note that this announcement is made on a voluntary basis for the purpose of keeping the public informed of the latest business developments of the Company. Further announcement in relation to the Strategic Cooperation will be made by the Company in compliance with the Listing Rules, where applicable.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GoFintech Quantum Innovation Limited
SUN Qing
Chairlady and Executive Director

Hong Kong, 8 May 2026

As at the date of this announcement, the Board consists of one executive Director, namely Ms. SUN Qing (Chairlady); two non-executive Directors, namely Dr. NIE Riming and Mr. LI Chunguang; and three independent non-executive Directors, namely Mr. CHIU Kung Chik, Ms. LUI Mei Ka and Dr. LIANG Jinxiang.

* *For identification purpose only*